Analysts skeptical as AstraZeneca sales, earnings sink

Tracy Staton AstraZeneca's ($ AZN) first-quarter sales dropped by 12%. Core earnings fell by 21%. Neither number approached Bristol-Myers Squibb's ($ BMY) scary declines. ...

Radius nabs $43M round for PhIII bone-building drug

John Carroll Radius Health joined the lineup of biotechs announcing big new venture rounds today. The Cambridge, MA-based developer, which is focused on new therapies for osteoporosis, ...

Bayer drug sales up 2.3%, as new products offset older drugs’ suffering

Tracy Staton Poor Bayer HealthCare. Its new drugs and modest sales growth couldn't make up for lagging sales and soaring costs at Bayer's plastics business. Announcing its ...

Experienced biotech team snags $33M for promising PhII cholesterol drug

John Carroll   Now that the successful biopharma team of Roger Newton and Tim Mayleben has reunited to run an upstart–Esperion–with a promising mid-stage cholesterol ...

AstraZeneca’s PhIII chief scouts for blockbuster deals as revenue slides

John Carroll AstraZeneca ($ AZN) today had another big round of dismal revenue numbers to explain today. With generic rivals tearing at some of its key franchises, the pharma giant ...

Busy Novartis announces layoffs, taps new CFO, and slashes chairman’s pay

Tracy Staton While the U.S. government was announcing its kickbacks lawsuit against Novartis, the Swiss drugmaker was putting the finishing touches on a few press releases of its own. ...

French biotech Genticel lands $23.7M for ‘blockbuster’ HPV vaccine hopeful

Ryan McBride Some top life sciences investors have backed France-based vaccine developer Genticel in an €18.2 million round of venture financing. The company plans to spend the ...

Lilly cost-cutting and price hikes pay off with Q1 earnings beat

Tracy Staton The moral of Eli Lilly's first-quarter performance is this: Raise prices and cut costs. The drugmaker ($ LLY) beat analyst expectations on earnings, partly because ...

Achaogen nails $60M in government funding to push antibiotics pipeline

Emily Mullin Antibiotics maker Achaogen announced today that it has landed a $ 60 million contract option from the federal Biomedical Advanced Research and Development Authority (BARDA) ...

Is GlaxoSmithKline prepping older products for spinoff?

Tracy Staton GlaxoSmithKline's waiting game continues. The U.K.-based drugmaker ($ GSK) posted disappointing profits for the first quarter as sales took a backwards step, partly ...

Novartis changes CFOs, reveals cuts to work force and chairman pay

Alok Saboo While the U.S. government was announcing its kickbacks lawsuit against Novartis, the Swiss drugmaker was putting the finishing touches on a few press releases of its own. ...

Merck nabs ‘breakthrough’ label for anti-melanoma drug

Tracy Staton Merck ($ MRK) won the FDA's "Breakthrough Therapy" tag for its experimental antibody drug lambrolizumab, aimed at advanced melanoma. The designation was ...
Page 5 of 17« First...34567...10...Last »
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS